Pancreatic cancer remains one of the leading causesof cancer related death worldwide with an overall fiveyear survival of less than 5%.Potentially curative surgery,which alone can improve 5-year survival to 10%,is an option for only 10%-20%of patients at presentation owing to local invasion of the tumour or metastaticdisease.Adjuvant chemotherapy has been shown toimprove 5-year survival to 20%-25%but conflicting evidence remains with regards to chemoradiation.In thisarticle we review the current evidence available frompublished randomised trials and discuss ongoing phaseⅢtrials in relation to adjuvant therapy in pancreaticcancer. Pancreatic cancer remains one of the leading causes of cancer related death worldwide with an overall fiveyear survival of less than 5% .Potentially curative surgery, which alone can improve 5-year survival to 10%, is an option for only 10% -20% of patients at presentation owing to local invasion of the tumor or metastatic disease. Adjuvant chemotherapy has been shown toimprove 5-year survival to 20% -25% but conflicting evidence remains with to chemoradiation. this article we review the current evidence available from randomly-established trials and discuss ongoing phase Ⅲtrials in relation to adjuvant therapy in pancreatic cancer.